Eli Lilly & Co. and Incyte Corp. reported on Sept. 29 that baricitinib bested the first-line rheumatoid arthritis (RA) standard of care methotrexate in a late-stage clinical trial, so now the partners must complete just one more Phase III trial before seeking regulatory approvals for the JAK inhibitor.
Another Positive Phase III For Lilly's, Incyte's Baricitinib
Eli Lilly & Co. and Incyte Corp. reported on Sept. 29 that baricitinib bested the first-line rheumatoid arthritis (RA) standard of care methotrexate in a late-stage clinical trial, so now the partners must complete just one more Phase III trial before seeking regulatory approvals for the JAK inhibitor.
More from Anti-infective
• By
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
• By
Professor Anil Koul shares vignettes of his life and career trajectory, a captivating mix of hope, science and destiny that took him to the lab of eminent cancer biologist Alex Ullrich at the Max Planck Institute and also saw him contribute to the development of breakthrough TB drug bedaquiline. He also talks about Medicine 3.0 and the intersection of science and spirituality.
• By
The company is developing doravirine and islatravir together as an alternative to therapies containing integrase inhibitors, like Biktarvy, especially as HIV patients age.
• By
The two companies were among those presenting data at CROI that highlighted the next frontiers of competition in the HIV space.
More from Therapy Areas
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.